Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2018 / Cilt: 28 - Sayı: 4

Prognostic Significance of the Glasgow Prognostic Score in Patients Undergoing Pulmonary Metastasectomy

Pulmoner Metastazektomi Uygulanan Hastalarda Glasgow Prognostik Skoru’nun Prognostic Önemi

Pages
224–229
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although there is an evident decline of mean survival in breast cancer and sarcoma patients, theeffect of GPS score on overall survival was statistically insignificant (p= 0.081 and p= 0.056, respectively).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pulmonary metastasectomy is considered the standard treatment for various cancer types when the primary tumour is under control.The Glasgow Prognostic Score (GPS), which is determined by serum levels of C-reactive protein (CRP) and albumin, is found to bea potential prognostic tool for variable primary cancer types.
📊
Key Findings & Data:Data of 142 patients who underwent pulmonary metastasectomy at in a single institution were retrospectively analyzed from a prospectively collected database.
💡
Conclusion & Impact:Although there is an evident decline of mean survival in breast cancer and sarcoma patients, theeffect of GPS score on overall survival was statistically insignificant (p= 0.081 and p= 0.056, respectively).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Pulmonary metastasectomy is considered the standard treatment for various cancer types when the primary tumour is under control.The Glasgow Prognostic Score (GPS), which is determined by serum levels of C-reactive protein (CRP) and albumin, is found to bea potential prognostic tool for variable primary cancer types. The aim of this study is to evaluate the prognostic role of the GPS inpatients undergoing pulmonary metastasectomy for different subgroups of cancer types. Data of 142 patients who underwent pulmonary metastasectomy at in a single institution were retrospectively analyzed from a prospectively collected database. Primary tumourhistologic subtypes were classified into five categories: Gastrointestinal tumours (Colorectal, gastric and colangiocellular carcinomas,n= 43), sarcomas (osteosarcoma, chondrosarcoma and synovial sarcoma, n= 38), breast carcinoma (n= 16), genitourinary systemcarcinomas (Cervix and endometrium carcinomas, n= 10) and miscellaneous (n= 35). High GPS is found to be correlated with worsesurvival rates in the subgroups of pulmonary metastasectomy for gastrointestinal, genitourinary and miscellaneous cancers (p= 0.050,p= 0.046 and p= 0.003, respectively). Although there is an evident decline of mean survival in breast cancer and sarcoma patients, theeffect of GPS score on overall survival was statistically insignificant (p= 0.081 and p= 0.056, respectively). In conclusion, GPS appearsto be a useful predictor of overall survival in pulmonary metastases for the majority of cancer types.

Özet

Primer tümörün kontrol altında olduğu izole akciğer metastazı bulunan birçok kanser türünde pulmoner metastazektomi standart tedavi olarak kabul edilir. Glasgow prognostik skoru (GPS) serumdaki C-reaktif protein ve albümin değerleri arasındaki ilişki ile elde edilir ve bazı primer kanser türleri için potansiyel bir prognostik faktördür. Bu çalışmanın amacı, bazı kanser türlerinde pulmoner metastazektomi uygulanan hastalarda GPS skorunun prognostik rolünü incelemektir. Bu amaçla, pulmoner metastazektomi uygulanmış olan toplam 142 hastanın verileri retrospektif olarak incelendi. Hastalar primer tümörlerinin histolojik tiplerine göre beş gruba ayrıldı: Gastrointestinal tümörler (Kolorektal, gastrik ve kolanjiyoselüler karsinomlar, n= 43), sarkomlar (Osteosarkom, kondrosarkom ve sinoviyal sarkom, n= 38), meme karsinomu (n= 16), genitoüriner sistem karsinomları (Serviks ve endometriyum, n= 10) ve mikst karsinomlar grubu (n= 35). GİS, GÜS ve mikst karsinomlu hastalarda GPS skorunun yüksekliği ile kötü sağkalım arasındaki ilişki istatistiksel olarak anlamlı bulundu (sırası ile p= 0.05, p= 0.046 ve p= 0.03). Sarkom ve meme karsinomu gruplarında ise GPS skoru yüksek olan hastaların prognozunun daha kötü olduğu saptanmasına rağmen ilişki istatistiksel olarak anlamlı bulunmadı (sırası ile p= 0.056 ve p= 0.081). Sonuç olarak, GPS skoru birçok kanser türünde metastatik akciğer kanserlerinin sağkalımını değerlendirmek amacıyla potansiyel prognostik bir belirteç olarak kullanılabilir.

🔖

Cite This Article

KARAHAN, S., DEMİRCİN, M., DOĞAN, R., KUMBASAR, U., DİKMEN, E., ÖZERCAN, M. (2022). Prognostic Significance of the Glasgow Prognostic Score in Patients Undergoing Pulmonary Metastasectomy. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 28 - Sayı: 4, 224–229. https://ajindex.com/articles/644783

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Treasure T, Milosevic M, Fiorentino F, Macbeth F. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax 69: 946-949, 2014
  2. Mineo TC, Tacconi F. Role of systemic inflammation scores in pulmonary metastasectomy for colorectal cancer. Thorac Cancer 5: 431-437, 2014
  3. Schweiger T, Lang G, Klepetko W, Hoetzenecker K. Prognostic factors in pulmonary metastasectomy: spotlight on molecular and radiological markers. Eur J Cardiothorac Surg 45: 408-416, 2014
  4. Ghanim B, Schweiger T, Jedamzik J, et al. Elevated inflammatory parameters and inflammation scores are associated with poor prognosis in patients undergoing pulmonary metastasectomy for colorectal cancer. Interact Cardiovasc Thorac Surg 21: 616-623, 2015
  5. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39: 534-540, 2013
  6. Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. British journal of cancer 97: 1266-1270, 2007
  7. Hofmann HS, Neef H, Krohe K, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48: 77-81, 2005
  8. Welter S, Jacobs J, Krbek T, et al. Pulmonary metastases of breast cancer. When is resection indicated? Eur J Cardiothorac Surg 34: 1228-1234, 2008
  9. Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113: 37-49, 1997
  10. Suzuki M, Iwata T, Ando S, et al. Predictors of long-term survival with pulmonary metastasectomy for osteosarcomas and soft tissue sarcomas. J Thorac Cardiovasc Surg 47: 603- 608, 2006
  11. Chen F, Miyahara R, Bando T, et al. Prognostic factors of pulmonary metastasectomy for osteosarcomas of the extremities. Eur J Cardiothorac Surg 34: 1235-1239, 2008
  12. Kawashima M, Murakawa T, Shinozaki T, et al. Significance of the Glasgow Prognostic Score as a prognostic indicator for lung cancer surgery. Interact Cardiovasc Thorac Surg 21: 637-643, 2015
  13. Miyazaki T, Yamasaki N, Tsuchiya T, et al. Inflammationbased scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-smallcell lung cancer. Eur J Cardiothorac Surg 47: e140-5, 2015
  14. Hwang EC, Hwang IS, Yu HS, et al. Utility of inflammationbased prognost